Novavax to seek full approval for COVID-19 vaccine in second half of 2022
Novavax plans to pursue full approval for its COVID-19 vaccine during the second half of 2022, following a late-stage study showing sustained efficacy and a forecast of $4 billion to $5 billion in revenue.